Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 10:46 ET | Source: IO Biotech

IO Biotech Announces Participation in Upcoming December Investor Conferences

IO Biotech Announces Participation in Upcoming December Investor Conferences
November 14, 2025 08:05 ET | Source: IO Biotech

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 12, 2025 08:30 ET | Source: IO Biotech

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences
November 07, 2025 09:00 ET | Source: IO Biotech

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the SITC 2025 Annual Meeting
October 20, 2025 02:30 ET | Source: IO Biotech

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
September 29, 2025 07:05 ET | Source: IO Biotech

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

IO Biotech Provides Update Following Pre-BLA Meeting with FDA
September 23, 2025 08:05 ET | Source: IO Biotech

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
September 04, 2025 08:05 ET | Source: IO Biotech

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences
August 14, 2025 16:05 ET | Source: IO Biotech

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 11, 2025 08:00 ET | Source: IO Biotech

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab...